Page 2
Lab News

Peter and Takako Jones Lab

Page 2

Jones Lab attends the FSHS Patient Connect meeting in Las Vegas

June 9, 2018

The Jones lab attended the bi-annual FSH Society Patient Connect meeting in Las Vegas.  We met with patients and families, answering questions and discussing research progress.  Dr. Charis Himeda was a panelist for teh session on FSHD Therapeutic Development and discussed her CRISPR work.

Peter Jones presents at the Gordon Research Conference on Epigenomics of Diabetes and other Metabolic Diseases

May 30, 2018

Peter Jones was invited to attend the inaugural Gordon Research Conference on Epigenomics of Diabetes and other Metabolic Diseases in Hong Kong.  Dr. Jones presented a talk, "FSHD is a model for epigenetic mechanisms, diagnostics, and therapy", using FSHD as an example for how to approach epigenetic diseases and epigenetic aspects for genetic diseases.

Monique Ramirez receives Nevada INBRE award

April 24, 2018

Congratulations to Monique Ramirez, an undergraduate researcher in the Jones Lab, whoe received a 2018 Undergraduate Research Opportunities Program award from the Nevada INBRE for the summer.  This award provides a stipend for the summer, weekly career development workshops, and a research poster session in August for presenting her work.  She will be working on characterizing the new FSHD-like mouse models the lab had developed.

Charis Himeda publishes in Molecular Therapy

April 20, 2018

Dr. Charis Himeda's paper "Identification of epigenetic regulators of DUX4-fl for targeted tehrapy of facioscapulohumeral muscular dystrophy" was published today in Molecular Therapy.  This work shows that the SMARCA5, ASH1L, and BAZ1A proteins each are highly specific FSHD thereapeutic targets for designing small inhibitory molecules.

FLExDUX4 FSHD-like mouse published

February 8, 2018

The initial characterization of Dr. Takako Jones' FSHD-like cre-inducible transgenic mouse model was published online today in PLoS One. This highly versitile model based on investigator controlled expression of the pathogenic DUX4 gene is the first phenotypic mouse that shows FSHD-like muscle histopathology and weakness.  This mouse model is easy to breed, healthy in the absence of cre induction, and can readily be scaled up and used for preclinical testing of potential FSHD therapeutics targeting DUX4 mRNA and protein. In addition, this mouse is already available from Jackson Labs for ease of import into academic and pharmaceutical labs.